• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Nat Med . Rapid SARS-CoV-2 whole-genome sequencing and analysis for informed public health decision-making in the Netherlands

tetano

Editor, Senior Moderator
Nat Med


. 2020 Jul 16.
doi: 10.1038/s41591-020-0997-y. Online ahead of print.
Rapid SARS-CoV-2 whole-genome sequencing and analysis for informed public health decision-making in the Netherlands


Bas B Oude Munnink[SUP] 1 [/SUP], David F Nieuwenhuijse[SUP] 1 [/SUP], Mart Stein[SUP] 2 [/SUP], ?ine O'Toole[SUP] 3 [/SUP], Manon Haverkate[SUP] 2 [/SUP], Madelief Mollers[SUP] 2 [/SUP], Sandra K Kamga[SUP] 2 [/SUP], Claudia Schapendonk[SUP] 1 [/SUP], Mark Pronk[SUP] 1 [/SUP], Pascal Lexmond[SUP] 1 [/SUP], Anne van der Linden[SUP] 1 [/SUP], Theo Bestebroer[SUP] 1 [/SUP], Irina Chestakova[SUP] 1 [/SUP], Ronald J Overmars[SUP] 1 [/SUP], Stefan van Nieuwkoop[SUP] 1 [/SUP], Richard Molenkamp[SUP] 1 [/SUP], Annemiek A van der Eijk[SUP] 1 [/SUP], Corine GeurtsvanKessel[SUP] 1 [/SUP], Harry Vennema[SUP] 2 [/SUP], Adam Meijer[SUP] 2 [/SUP], Andrew Rambaut[SUP] 3 [/SUP], Jaap van Dissel[SUP] 2 [/SUP], Reina S Sikkema[SUP] 1 [/SUP], Aura Timen[SUP] 2 [/SUP], Marion Koopmans[SUP] 4 [/SUP], Dutch-Covid-19 response team



Collaborators, Affiliations

Abstract

In late December 2019, a cluster of cases of pneumonia of unknown etiology were reported linked to a market in Wuhan, China[SUP]1[/SUP]. The causative agent was identified as the species Severe acute respiratory syndrome-related coronavirus and was named SARS-CoV-2 (ref. [SUP]2[/SUP]). By 16 April the virus had spread to 185 different countries, infected over 2,000,000 people and resulted in over 130,000 deaths[SUP]3[/SUP]. In the Netherlands, the first case of SARS-CoV-2 was notified on 27 February. The outbreak started with several different introductory events from Italy, Austria, Germany and France followed by local amplification in, and later also outside, the south of the Netherlands. The combination of near to real-time whole-genome sequence analysis and epidemiology resulted in reliable assessments of the extent of SARS-CoV-2 transmission in the community, facilitating early decision-making to control local transmission of SARS-CoV-2 in the Netherlands. We demonstrate how these data were generated and analyzed, and how SARS-CoV-2 whole-genome sequencing, in combination with epidemiological data, was used to inform public health decision-making in the Netherlands.
 
Back
Top Bottom